On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The Danish drugmaker and rival Eli Lilly have together sued dozens of medical spas, weight-loss clinics, compounding ...

U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

“Supply chain issues and the dominance of a few pharmaceutical companies keep prices of some products high and unaffordable ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Amgen is testing MariTide as a once-monthly shot, making it a promising potential rival to the weekly blockbuster weight-loss injections from Novo Nordisk and Eli Lilly. Tuesday's stock decline lopped ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...